ESC 365 - Oral anticoagulant treatment in patients with atrial fibrillation early after valvular intervention: a nationwide cohort study

ESC Professional Premium Access

Oral anticoagulant treatment in patients with atrial fibrillation early after valvular intervention: a nationwide cohort study

Session: Thrombosis and anticoagulation in valvular heart disease

Topic: Pharmacotherapy

Speaker: Associate Professor C. Christersson (Uppsala, SE)

Event: ESC Congress 2022

Congress Presentation

Add to my library

About the speaker

Associate Professor Christina Christersson

Uppsala University, Uppsala (Sweden)

5 presentations

2 followers

4 more presentations in this session

To compare efficacy and safety of direct oral anticoagulants in patients with concurrent atrial fibrillation and bioprosthetic heart valve repair or replacement: a systematic review and meta-analysis

Speaker: Doctor A. Kaur (New York City, US)

Comparing direct oral anticoagulants versus vitamin k antagonist in patients with atrial fibrillation after transcatheter aortic valve replacement: an updated meta-analysis

Speaker: Doctor A. Kaur (New York City, US)

Risk factors and clinical effects of late leaflet thrombosis after transcatheter aortic valve replacement

Speaker: Doctor M. Bak (Seoul, KR)

Hypoattenuated leaflet thickening is associated with silent brain injury

Speaker: Doctor A. Nagy (Budapest, HU)

Access the full session

Thrombosis and anticoagulation in valvular heart disease

Speakers: Associate Professor C. Christersson, Doctor A. Kaur, Doctor A. Kaur, Doctor M. Bak, Doctor A. Nagy

About the event

ESC Congress 2022

26 August - 29 August 2022

Sessions Presentations

Congress

ESC 365 is supported by

Explore sponsored resources

Explore sponsored resources